Prostate cancer chemotherapy in the era of targeted therapy (Q37180864)

18 August 2017

1 reference

title

Prostate cancer chemotherapy in the era of targeted therapy (English)

1 reference

18 August 2017

1 reference

1 reference

A Michael

1 reference

18 August 2017

K Syrigos

series ordinal

1 reference

18 August 2017

H Pandha

series ordinal

1 reference

18 August 2017

publication date

3 June 2008

1 reference

Prostate Cancer and Prostatic Diseases

18 August 2017

published in

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

page(s)

13-16

1 reference

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Preclinical antitumor activity of the oral platinum analog satraplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Vitamin D analogs: mechanism of action and therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Novel Molecular Signaling and Classification of Human Clinically Nonfunctional Pituitary Adenomas Identified by Gene Expression Profiling and Proteomic Analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.32

31 March 2020

Identifiers

DOI

10.1038/PCAN.2008.32

1 reference

Dimensions Publication ID

18 August 2017

1002741273

0 references

1 reference